

Giovanni Battista Migliori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3639503/publications.pdf>

Version: 2024-02-01

507
papers

26,494
citations

7672

79
h-index

10955

142
g-index

528
all docs

528
docs citations

528
times ranked

17983
citing authors

#	ARTICLE	IF	CITATIONS
1	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. <i>Pulmonology</i> , 2022, 28, 44-58.	1.0	10
2	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	3.1	11
3	Global reporting on tuberculosis preventive treatment among contacts. <i>European Respiratory Journal</i> , 2022, 59, 2102753.	3.1	7
4	Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series. <i>Pulmonology</i> , 2022, 28, 155-157.	1.0	1
5	Impact of the COVID-19 pandemic on tuberculosis services. <i>Pulmonology</i> , 2022, 28, 210-219.	1.0	17
6	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	0.8	9
7	Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. <i>Pulmonology</i> , 2022, 28, 297-309.	1.0	6
8	Commemorating World Tuberculosis Day 2022: recent <i>ERJ</i> articles of critical relevance to ending TB and saving lives. <i>European Respiratory Journal</i> , 2022, 59, 2200149.	3.1	0
9	Drug resistant TB “ latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	1.5	37
10	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 124, S12-S19.	1.5	42
11	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	1.5	18
12	The WHO Global Tuberculosis 2021 Report “ not so good news and turning the tide back to End TB. <i>International Journal of Infectious Diseases</i> , 2022, 124, S26-S29.	1.5	158
13	Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis. <i>Frontiers in Medicine</i> , 2022, 9, 870738.	1.2	16
14	War in Ukraine: an immense threat to the fight against tuberculosis. <i>European Respiratory Journal</i> , 2022, 59, 2200493.	3.1	8
15	Effects of COVID-19 on tuberculosis control: past, present, and future. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220102.	0.4	0
16	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20210515.	0.4	6
17	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.4	10
18	Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room. <i>Pulmonology</i> , 2021, 27, 35-42.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. Pulmonology, 2021, 27, 94-96.	1.0	10
20	Rationale for Anti-Tuberculosis Chemotherapy. , 2021, , 109-120.		0
21	National Tuberculosis Strategic Planning. , 2021, , 307-318.		0
22	Tuberculosis and COVID-19 Comorbidity: A New Twenty-First-Century Cursed Duet. , 2021, , 221-227.		0
23	Tuberculosis Infection Control. , 2021, , 67-76.		0
24	Different disease, same challenges: Social determinants of tuberculosis and COVID-19. Pulmonology, 2021, 27, 338-344.	1.0	35
25	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. International Journal of Infectious Diseases, 2021, 113, S82-S87.	1.5	64
26	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology, 2021, 27, 151-165.	1.0	172
27	Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 113, S96-S99.	1.5	32
28	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. Jornal Brasileiro De Pneumologia, 2021, 47, 20210044.	0.4	15
29	Tuberculosis Series 2021. Jornal Brasileiro De Pneumologia, 2021, 47, e20210109.	0.4	0
30	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology, 2021, 27, 248-256.	1.0	18
31	The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Archivos De Bronconeumologia, 2021, , .	0.4	4
32	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Authorsâ€™ reply. Jornal Brasileiro De Pneumologia, 2021, 47, e20210328.	0.4	3
33	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. European Respiratory Journal, 2021, 58, 2101786.	3.1	86
34	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Jornal Brasileiro De Pneumologia, 2021, 47, e20210076.	0.4	7
35	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe, 2021, 17, 210079.	0.6	59
36	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 713-722.	2.5	22

#	ARTICLE	IF	CITATIONS
37	Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. <i>Pulmonology</i> , 2021, 27, 452-455.	1.0	25
38	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021, 27, 403-412.	1.0	30
39	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	1.5	5
40	Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating. <i>The Lancet Global Health</i> , 2021, 9, e1628-e1629.	2.9	4
41	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	2.9	59
42	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. <i>Journal of Asthma</i> , 2020, 57, 1365-1371.	0.9	7
43	European guidance on drug-resistant tuberculosis in children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 9-11.	2.7	3
44	What is the best regimen to treat latent tuberculosis infection?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 263-264.	4.6	0
45	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	3.1	11
46	Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901467.	3.1	55
47	Developing health policies in patients presenting with SARS-CoV-2: consider tuberculosis. <i>The Lancet Global Health</i> , 2020, 8, e1357-e1358.	2.9	3
48	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
49	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
50	IJTLD Editorial Plan 2020–2025. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 559-561.	0.6	0
51	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. <i>Lancet</i> , The, 2020, 396, 402-411.	6.3	49
52	Intermittent regimens for tuberculosis treatment: Back to the Future?. <i>European Respiratory Journal</i> , 2020, 56, 2002510.	3.1	0
53	COVID-19 and tuberculosis—threats and opportunities. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 757-760.	0.6	45
54	Harnessing the energy of the corporate sector to end TB: BE health. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020, 21, 100206.	0.6	0

#	ARTICLE	IF	CITATIONS
55	New diseases and old threats: lessons from tuberculosis for the COVID-19 response. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 544-545.	0.6	49
56	Reply to Chang and Yew. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 778-779.	2.5	0
57	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. <i>Pulmonology</i> , 2020, 26, 233-240.	1.0	178
58	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	3.1	273
59	Management and outcomes of post-acute COVID-19 patients in Northern Italy. <i>European Journal of Internal Medicine</i> , 2020, 78, 159-160.	1.0	18
60	Mask wearing to complement social distancing and save lives during COVID-19. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 556-558.	0.6	33
61	How to demystify COVID-19 and reduce social stigma. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 640-642.	0.6	16
62	Tuberculosis in the time of COVID-19: quality of life and digital innovation. <i>European Respiratory Journal</i> , 2020, 56, 2001998.	3.1	28
63	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	0.8	4
64	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	1.5	6
65	Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	7
66	Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2020, 26, .	2.0	10
67	Pediatric tuberculosis in the metropolitan area of Rio de Janeiro. <i>International Journal of Infectious Diseases</i> , 2020, 98, 299-304.	1.5	3
68	On tuberculosis and COVID-19 co-infection. <i>European Respiratory Journal</i> , 2020, 56, 2002328.	3.1	93
69	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
70	Non-tuberculous mycobacterial infections "A neglected and emerging problem. <i>International Journal of Infectious Diseases</i> , 2020, 92, S46-S50.	1.5	46
71	A postgraduate qualification in tuberculosis "Message in a bottle. <i>International Journal of Infectious Diseases</i> , 2020, 92, S100-S102.	1.5	1
72	Post tuberculosis treatment infectious complications. <i>International Journal of Infectious Diseases</i> , 2020, 92, S41-S45.	1.5	36

#	ARTICLE	IF	CITATIONS
73	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	1.5	26
74	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	1.5	20
75	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	1.5	13
76	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	1.5	126
77	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	1.3	8
78	Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. <i>European Respiratory Journal</i> , 2020, 55, 2001260.	3.1	199
79	Monitoring adverse events of new drugs: a programmatic need stimulating operational research. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 360-361.	0.6	0
80	Celebrating World Tuberculosis Day at the time of COVID-19. <i>European Respiratory Journal</i> , 2020, 55, 2000650.	3.1	41
81	Shortened tuberculosis treatment regimens: what is new?. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200009-e20200009.	0.4	21
82	Tuberculosis series 2020. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200027-e20200027.	0.4	9
83	Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 700-705.	0.6	29
84	The need for pulmonary rehabilitation following tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 720-722.	0.6	25
85	Adapting our Journal for the new decade (and the next 100 years). <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 268-269.	0.6	0
86	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
87	Multidrug-resistant tuberculosis – Authors' reply. <i>Lancet, The</i> , 2019, 394, 299-300.	6.3	2
88	Multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2019, 394, 298.	6.3	10
89	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113
90	Multidrug and Extensively Drug-resistant Tuberculosis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 1063-1085.	1.9	25

#	ARTICLE	IF	CITATIONS
91	TB consilia and quality of tuberculosis management. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1048-1049.	0.6	4
92	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
93	Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. <i>European Respiratory Journal</i> , 2019, 53, 1802077.	3.1	28
94	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. <i>European Respiratory Review</i> , 2019, 28, 190035.	3.0	107
95	Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews. <i>European Respiratory Review</i> , 2019, 28, 180107.	3.0	15
96	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180420.	0.4	5
97	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
98	Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. <i>European Respiratory Journal</i> , 2019, 54, 1800353.	3.1	22
99	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, S457-S460.	0.6	9
100	Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180324.	0.4	27
101	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391.	3.1	81
102	Another aetiology for tuberculosisâ€”beyond the <i>Mycobacterium</i> . <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 277-277.	0.6	1
103	Prioritising children and adolescents in the tuberculosis response of the WHO European Region. <i>European Respiratory Review</i> , 2019, 28, 180106.	3.0	15
104	Launching the Global TB Network. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 123-124.	0.6	3
105	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , 2019, 53, 1802184.	3.1	51
106	Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA. <i>Infection</i> , 2019, 47, 353-361.	2.3	23
107	Challenging MDR-TB clinical problems â€” The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	1.5	21
108	World Tuberculosis Day March 24th 2019 Theme: â€œTIMEâ€” International Journal of Infectious Diseases Tuberculosis Theme Series. <i>International Journal of Infectious Diseases</i> , 2019, 80, S1-S5.	1.5	3

#	ARTICLE	IF	CITATIONS
109	Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1024-1028.	0.6	1
110	The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. <i>European Respiratory Journal</i> , 2019, 54, 1901272.	3.1	30
111	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	2.5	282
112	Regimen design and pharmacokineticâ€“pharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 3-4.	4.6	0
113	Evolution of Programmatic Definitions Used in Tuberculosis Prevention and Care. <i>Clinical Infectious Diseases</i> , 2019, 68, 1787-1789.	2.9	24
114	Delamanid: does it have a role in tuberculosis treatment?. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 193-195.	5.2	4
115	Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3534-3549.	0.7	13
116	Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190043.	0.4	5
117	Tuberculosis series 2019. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190064.	0.4	3
118	Adolescents and young adults: a neglected population group for tuberculosis surveillance. <i>European Respiratory Journal</i> , 2018, 51, 1800176.	3.1	16
119	Point of care diagnostics for tuberculosis. <i>Pulmonology</i> , 2018, 24, 73-85.	1.0	84
120	Multi and extensively drug-resistant pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 244-252.	1.2	21
121	New drugs and perspectives for new anti-tuberculosis regimens. <i>Pulmonology</i> , 2018, 24, 86-98.	1.0	114
122	Managing latent tuberculosis infection and tuberculosis in children. <i>Pulmonology</i> , 2018, 24, 106-114.	1.0	31
123	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Â“update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	3.1	50
124	Strengthening tuberculosis control to advance towards elimination: The 2018 Rev. Port. Pneumol. (RPP) TB Series. <i>Pulmonology</i> , 2018, 24, 67-68.	1.0	4
125	Predicting the effect of improved socioeconomic health determinants on the tuberculosis epidemic. <i>The Lancet Global Health</i> , 2018, 6, e475-e476.	2.9	8
126	Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 480-481.	4.6	10

#	ARTICLE	IF	CITATIONS
127	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141.	1.0	19
128	The impact of digital health technologies on tuberculosis treatment: a systematic review. <i>European Respiratory Journal</i> , 2018, 51, 1701596.	3.1	109
129	Tuberculosis elimination: a dream or a reality? The case of Oman. <i>European Respiratory Journal</i> , 2018, 51, 1702027.	3.1	18
130	Defining the best regimen to treat isoniazid-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 233-235.	5.2	1
131	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702187.	3.1	1
132	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. <i>EBioMedicine</i> , 2018, 29, 11-12.	2.7	5
133	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 "Wanted: Leaders for a TB-Free World. You can make history. End TB" <i>International Journal of Infectious Diseases</i> , 2018, 68, 122-124.	1.5	9
134	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. <i>European Respiratory Journal</i> , 2018, 51, 1702267.	3.1	10
135	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e198.	4.6	281
136	The World Health Organization standards for tuberculosis care and management. <i>European Respiratory Journal</i> , 2018, 51, 1800098.	3.1	57
137	Hoja de ruta para la eliminación de la tuberculosis en Latinoamérica y el Caribe. <i>Archivos De Bronconeumologia</i> , 2018, 54, 7-9.	0.4	8
138	Diagnostic performances of the Xpert MTB/RIF in Brazil. <i>Respiratory Medicine</i> , 2018, 134, 12-15.	1.3	13
139	Roadmap for Tuberculosis Elimination in Latin America and the Caribbean. <i>Archivos De Bronconeumologia</i> , 2018, 54, 7-9.	0.4	6
140	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. <i>Breathe</i> , 2018, 14, 269-275.	0.6	1
141	Eliminating tuberculosis in Latin America: making it the point. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 73-76.	0.4	10
142	The European Respiratory Society's 10 Principles for Lung Health. <i>European Respiratory Journal</i> , 2018, 52, 1801373.	3.1	6
143	European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations. <i>European Respiratory Journal</i> , 2018, 52, 1801617.	3.1	4
144	Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 2-2.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1247-1255.	1.5	6
146	Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes. <i>European Respiratory Journal</i> , 2018, 52, 1801449.	3.1	19
147	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	25
148	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
149	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. <i>European Respiratory Journal</i> , 2018, 51, 1702604.	3.1	15
150	Tuberculosis in the news: How do Portuguese media cover TB. <i>Pulmonology</i> , 2018, 24, 69-72.	1.0	2
151	Professor Massimo Amicosante, 1968â€“2017. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 236-236.	0.6	0
152	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	3.1	59
153	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	3.0	76
154	Global TB Network: working together to eliminate tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 347-349.	0.4	18
155	Tuberculosis series. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 71-72.	0.4	7
156	Management of tuberculosis in the European Union: a multicentre audit. , 2018, , .		0
157	Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery. , 2018, , .		0
158	Management of extensively drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 237-239.	5.2	1
159	Target regimen profiles for treatment of tuberculosis: a WHO document. <i>European Respiratory Journal</i> , 2017, 49, 1602352.	3.1	25
160	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.4	23
161	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.4	23
162	Tuberculosis elimination and the challenge of latent tuberculosis. <i>Presse Medicale</i> , 2017, 46, e13-e21.	0.8	48

#	ARTICLE	IF	CITATIONS
163	World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era. International Journal of Infectious Diseases, 2017, 56, 1-5.	1.5	19
164	Breaking the barriers: Migrants and tuberculosis. Presse Medicale, 2017, 46, e5-e11.	0.8	26
165	De-isolation of patients with pulmonary tuberculosis after start of treatment “ clear, unequivocal guidelines are missing. International Journal of Infectious Diseases, 2017, 56, 34-38.	1.5	13
166	Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015. European Respiratory Journal, 2017, 49, 1602309.	3.1	25
167	Effectiveness of post-migration tuberculosis screening. Lancet Infectious Diseases, The, 2017, 17, 684-685.	4.6	2
168	Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. European Respiratory Journal, 2017, 49, 1700374.	3.1	50
169	The long and winding road of chest radiography for tuberculosis detection. European Respiratory Journal, 2017, 49, 1700364.	3.1	13
170	Standard operating procedures for tuberculosis care. European Respiratory Journal, 2017, 49, 1700515.	3.1	6
171	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	3.1	233
172	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	3.1	11
173	World TB Day 2017: Strengthening the fight against TB. Presse Medicale, 2017, 46, e1-e4.	0.8	2
174	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. European Respiratory Journal, 2017, 49, 1700146.	3.1	59
175	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601612.	3.1	16
176	Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. European Respiratory Journal, 2017, 49, 1602445.	3.1	63
177	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 688-694.	1.1	35
178	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. International Journal of Infectious Diseases, 2017, 56, 30-33.	1.5	22
179	European policies in the management of tuberculosis among migrants. International Journal of Infectious Diseases, 2017, 56, 85-89.	1.5	22
180	Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. Revista Portuguesa De Pneumologia, 2017, 23, 27-30.	0.7	11

#	ARTICLE	IF	CITATIONS
181	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2017, 49, 1600993.	3.1	20
182	Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?. <i>European Respiratory Journal</i> , 2017, 49, 1602273.	3.1	1
183	Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 159-161.	5.2	10
184	Prevention of tuberculosis transmission through medical surveillance systems. <i>Lancet Public Health</i> , 2017, 2, e439-e440.	4.7	1
185	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases</i> , 2017, 17, 898.	4.6	9
186	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. <i>International Journal of Infectious Diseases</i> , 2017, 65, 133-134.	1.5	3
187	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	3.1	103
188	Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. <i>European Respiratory Journal</i> , 2017, 50, 1701632.	3.1	12
189	Bedaquiline: how better to use it. <i>European Respiratory Journal</i> , 2017, 50, 1701670.	3.1	6
190	Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2017, 50, 1700648.	3.1	32
191	Tuberculosis, alcohol and tobacco: Dangerous liaisons. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 177-178.	0.7	3
192	Tuberculosis control, and the where and why of artificial intelligence. <i>ERJ Open Research</i> , 2017, 3, 00056-2017.	1.1	22
193	Reply to Alffenaar et al. <i>Clinical Infectious Diseases</i> , 2017, 64, 105-106.	2.9	3
194	Applicability of the shorter "Bangladesh regimen"™ in high multidrug-resistant tuberculosis settings. <i>International Journal of Infectious Diseases</i> , 2017, 56, 190-193.	1.5	38
195	WHO Strategies for the Management of Drug-Resistant Tuberculosis. <i>Archivos De Bronconeumología</i> , 2017, 53, 95-97.	0.4	5
196	Time to review treatment of isoniazid-resistant tuberculosis?. <i>Lancet Infectious Diseases</i> , 2017, 17, 127-128.	4.6	2
197	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1300-1310.	2.5	61
198	Antituberculosis Agents. , 2017, , 1264-1276.e2.		1

#	ARTICLE	IF	CITATIONS
199	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	1.5	82
200	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.4	6
201	Genotypic and phenotypic <i>M. tuberculosis</i> resistance: guiding clinicians to prescribe the correct regimens. <i>European Respiratory Journal</i> , 2017, 50, 1702292.	3.1	9
202	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	3.1	21
203	Understanding the multidrug-resistant tuberculosis epidemic in China. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 955-955.	0.6	1
204	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	2.0	43
205	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 341.	1.8	47
206	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.4	26
207	Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 727-736.	0.6	27
208	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	0.6	52
209	Post-implementation blues: the unfulfilled potential of Xpert. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1073-1073.	0.6	1
210	Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress. <i>Journal of Thoracic Disease</i> , 2017, 9, S1559-S1562.	0.6	0
211	OBSOLETE: Tuberculosis, Public Health Aspects. , 2017, , .		0
212	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
213	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. <i>Indian Journal of Medical Research</i> , 2017, 145, 261-263.	0.4	0
214	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. <i>Journal of Thoracic Disease</i> , 2016, 8, 2666-2671.	0.6	39
215	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. <i>Journal of Thoracic Disease</i> , 2016, 8, E474-E485.	0.6	45
216	Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels. <i>Journal of Thoracic Disease</i> , 2016, 8, 3307-3313.	0.6	3

#	ARTICLE	IF	CITATIONS
217	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 374-385.	0.4	45
218	Monitoring Therapy Adherence of Tuberculosis Patients by using Video-Enabled Electronic Devices. <i>Emerging Infectious Diseases</i> , 2016, 22, 538-540.	2.0	66
219	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 373.	1.8	75
220	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0151724.	1.1	12
221	Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. <i>European Respiratory Journal</i> , 2016, 48, 1571-1581.	3.1	35
222	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1288-1290.	3.1	12
223	The ERS Research Agency: the beginning. <i>European Respiratory Journal</i> , 2016, 47, 1017-1023.	3.1	13
224	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	3.1	69
225	Advancing global programmatic management of latent tuberculosis infection for at risk populations. <i>European Respiratory Journal</i> , 2016, 47, 1327-1330.	3.1	22
226	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	3.1	27
227	Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	3.1	66
228	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	3.1	5
229	The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 963-971.	3.1	30
230	Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 337-341.	0.7	11
231	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	3.1	75
232	New anti-tuberculosis drugs for special populations: a difficult-to-address issue. <i>European Respiratory Journal</i> , 2016, 48, 957-958.	3.1	5
233	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	2.9	916
234	Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, 853-867.	2.9	237

#	ARTICLE	IF	CITATIONS
235	Better data, more tailored tuberculosis therapies. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1096-1097.	4.6	3
236	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	3.1	19
237	WHO recommendations for multidrug-resistant tuberculosis – Authors’ reply. <i>Lancet</i> , The, 2016, 388, 2234-2235.	6.3	1
238	TB-related mortality: a re-emerging problem in high-income countries?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 428-428.	0.6	1
239	Recent developments in the diagnosis and management of tuberculosis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16078.	1.1	58
240	Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care. <i>European Respiratory Journal</i> , 2016, 48, 1278-1281.	3.1	7
241	Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance. <i>European Respiratory Journal</i> , 2016, 48, 1282-1287.	3.1	20
242	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. <i>European Respiratory Journal</i> , 2016, 48, 1527-1529.	3.1	28
243	Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis. <i>Medicine (United States)</i> , 2016, 95, e5347.	0.4	14
244	WHO strategies for the programmatic management of drug-resistant tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 991-1002.	1.0	34
245	Digital health for the End TB Strategy: developing priority products and making them work. <i>European Respiratory Journal</i> , 2016, 48, 29-45.	3.1	61
246	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2016, 387, 2486-2487.	6.3	47
247	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	3.1	71
248	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	3.1	84
249	Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. <i>European Respiratory Journal</i> , 2016, 48, 946-952.	3.1	25
250	Clinical trials: registration and transparency. <i>European Respiratory Journal</i> , 2016, 47, 1342-1344.	3.1	6
251	Recommendations for treating children with drug-resistant tuberculosis. <i>Pharmacological Research</i> , 2016, 105, 176-182.	3.1	17
252	Recommendations for pediatric tuberculosis vaccination in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 644-650.	1.4	2

#	ARTICLE	IF	CITATIONS
253	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. <i>European Respiratory Journal</i> , 2016, 47, 664-667.	3.1	23
254	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. <i>Paediatric Drugs</i> , 2016, 18, 13-23.	1.3	11
255	Tuberculosisâ€™ advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e34-e46.	4.6	223
256	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	3.1	34
257	World TB Day 2016: reflections on the global TB emergency. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 249-251.	5.2	6
258	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. <i>European Respiratory Journal</i> , 2016, 47, 686-688.	3.1	17
259	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	3.1	136
260	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1188.2-1190.	2.9	34
261	The European Respiratory Society evaluates its 2013â€™2018 strategic plan implementation. <i>European Respiratory Journal</i> , 2016, 47, 693-698.	3.1	3
262	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	3.1	92
263	Low paediatric tuberculosis case detection rate in Southern Mozambique. <i>European Respiratory Journal</i> , 2016, 47, 1003-1005.	3.1	19
264	Tuberculosis management and determinants of recurrence. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 3-3.	0.6	4
265	Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis. <i>Clinical Therapeutics</i> , 2016, 38, 180-190.	1.1	7
266	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	3.1	64
267	Long-term protectiveness of BCG. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 140-142.	4.6	0
268	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		0
269	Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus. , 2016, , .		0
270	Digital health technology for the end TB strategy: Developing priority products and making them work. , 2016, , .		2

#	ARTICLE	IF	CITATIONS
271	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
272	Monitoring predictors of mortality: A necessary action to reach TB elimination. Revista Portuguesa De Pneumologia, 2015, 21, 295-298.	0.7	4
273	Greek Gods and Portuguese Pneumology: implementing HERMES. Revista Portuguesa De Pneumologia, 2015, 21, 291-292.	0.7	1
274	The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of SÃ£o Paulo, Brazil: a report of three cases. Jornal Brasileiro De Pneumologia, 2015, 41, 554-559.	0.4	9
275	New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research, 2015, 1, 00010-2015.	1.1	65
276	Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. European Respiratory Journal, 2015, 45, 25-29.	3.1	76
277	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 101-104.	1.5	36
278	Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy. European Respiratory Journal, 2015, 46, 274-277.	3.1	4
279	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. European Respiratory Journal, 2015, 46, 1841-1843.	3.1	0
280	Automated Digital Microscopy in New Tuberculosis Diagnostic Algorithms. Can It Boost Case Finding?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1352-1353.	2.5	9
281	Diabetes and tuberculosis: what else beyond?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1127-1128.	0.6	4
282	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	3.1	9
283	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. European Respiratory Journal, 2015, 45, 287-289.	3.1	19
284	Global Tuberculosis Elimination: The Relevance of Trend Surveillance in Mexico and Beyond. Archivos De Bronconeumologia, 2015, 51, 3-4.	0.4	1
285	Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2015, 13, 305-315.	2.0	39
286	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. European Respiratory Journal, 2015, 45, 289-291.	3.1	14
287	Tuberculosis Treatment and Drug Regimens. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017822-a017822.	2.9	131
288	Bedaquiline: finding the pores on the pot. European Respiratory Journal, 2015, 46, 289-291.	3.1	5

#	ARTICLE	IF	CITATIONS
289	Tuberculosis control in prisons: current situation and research gaps. <i>International Journal of Infectious Diseases</i> , 2015, 32, 111-117.	1.5	113
290	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	3.1	47
291	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. <i>International Journal of Infectious Diseases</i> , 2015, 32, 156-160.	1.5	19
292	Drug Resistance in <i>Mycobacterium tuberculosis</i> . <i>Chest</i> , 2015, 147, 1135-1143.	0.4	42
293	Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. <i>European Respiratory Journal</i> , 2015, 45, 317-321.	3.1	21
294	New effective antituberculosis regimens. <i>Lancet</i> , The, 2015, 385, 1703-1704.	6.3	7
295	Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 220-234.	5.2	172
296	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	3.1	608
297	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. <i>European Respiratory Journal</i> , 2015, 45, 1170-1173.	3.1	15
298	Untreatable tuberculosis: is surgery the answer?. <i>European Respiratory Journal</i> , 2015, 45, 577-582.	3.1	24
299	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	3.1	475
300	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 61, S102-S118.	2.9	74
301	The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation. <i>European Respiratory Journal</i> , 2015, 46, 307-311.	3.1	20
302	Assessing tuberculosis management: what really happens to patients?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1249-1251.	4.6	1
303	Management of drug resistant TB in patients with HIV co-infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2737-2750.	0.9	10
304	How to manage children who have come into contact with patients affected by tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2015, 1, 1-12.	0.6	9
305	Compassionate and optimum use of new tuberculosis drugs. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1131-1132.	4.6	32
306	Facing multi-drug resistant tuberculosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 144-148.	1.1	28

#	ARTICLE	IF	CITATIONS
307	The multidrug-resistant tuberculosis threat: old problems and new solutions. <i>Journal of Thoracic Disease</i> , 2015, 7, E354-60.	0.6	8
308	Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium. , 2015, , .		1
309	Joint WHO/ERS initiative on e-/m-Health for TB and tobacco control. , 2015, , .		0
310	Out-patient MDR-TB care in Moldova. , 2015, , .		0
311	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. <i>Journal of Thoracic Disease</i> , 2015, 7, 1080-5.	0.6	8
312	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. <i>European Respiratory Journal</i> , 2014, 44, 1412-1417.	3.1	32
313	Results of a tuberculin skin testing survey in Albania. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 310-314.	0.5	5
314	Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. <i>European Respiratory Journal</i> , 2014, 43, 1563-1566.	3.1	36
315	Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. <i>European Respiratory Journal</i> , 2014, 43, 1159-1171.	3.1	74
316	Toward Tuberculosis Elimination in Low-Incidence Countries: Reflections From a Global Consultation. <i>Annals of Internal Medicine</i> , 2014, 161, 670.	2.0	9
317	Extra-pulmonary tuberculosis: the comorbidity of the near future?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1389-1389.	0.6	5
318	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. <i>European Respiratory Journal</i> , 2014, 43, 286-289.	3.1	32
319	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	3.1	96
320	The European Respiratory Society plans its future: the 2013-2018 strategic plan. <i>European Respiratory Journal</i> , 2014, 43, 927-932.	3.1	15
321	Bacille Calmette-Guerin vaccination: the current situation in Europe. <i>European Respiratory Journal</i> , 2014, 43, 24-35.	3.1	33
322	Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider. <i>European Respiratory Journal</i> , 2014, 43, 678-684.	3.1	12
323	Tuberculosis elimination: dream or reality? The case of Cyprus. <i>European Respiratory Journal</i> , 2014, 44, 543-546.	3.1	46
324	Drug resistance and tuberculosis elimination in low-incidence countries. <i>European Respiratory Journal</i> , 2014, 44, 1408-1411.	3.1	7

#	ARTICLE	IF	CITATIONS
325	The European Union standards for tuberculosis care: do they need an update?. European Respiratory Journal, 2014, 43, 933-942.	3.1	30
326	Measuring the effect of tuberculosis control: a step forward. Lancet, The, 2014, 383, 2026-2028.	6.3	8
327	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respiratory Medicine, the, 2014, 2, 321-338.	5.2	237
328	Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. Expert Review of Anti-Infective Therapy, 2014, 12, 633-647.	2.0	100
329	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	2.9	116
330	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. European Respiratory Journal, 2014, 43, 289-292.	3.1	54
331	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	3.1	148
332	Is tuberculosis elimination a reality?. Lancet Infectious Diseases, The, 2014, 14, 364-365.	4.6	16
333	A new paradigm for multidrug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 884-884.	0.6	1
334	Survey of tuberculosis drug resistance among Tibetan refugees in India. International Journal of Tuberculosis and Lung Disease, 2014, 18, 655-662.	0.6	17
335	Risk Factors for Tuberculosis in Foreign-Born People (FBP) in Italy: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e94728.	1.1	19
336	Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. European Respiratory Journal, 2013, 41, 491-494.	3.1	58
337	<i>In vitro</i> susceptibility testing and totally drug-resistant tuberculosis. European Respiratory Journal, 2013, 42, 292-292.	3.1	4
338	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	3.1	211
339	The history and evolution of immigration medical screening for tuberculosis. Expert Review of Anti-Infective Therapy, 2013, 11, 137-146.	2.0	33
340	Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. European Respiratory Journal, 2013, 42, 785-801.	3.1	163
341	Efficacy and safety of meropenem+clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal, 2013, 41, 1386-1392.	3.1	145
342	Do we need a new Fleming <i>À</i> poque: The nightmare of drug-resistant tuberculosis. International Journal of Mycobacteriology, 2013, 2, 123-125.	0.3	9

#	ARTICLE	IF	CITATIONS
343	History of Tuberculosis and Drug Resistance. <i>New England Journal of Medicine</i> , 2013, 368, 88-90.	13.9	30
344	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	3.1	226
345	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 529-539.	4.6	243
346	Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 349-361.	4.6	385
347	Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 436-448.	4.6	246
348	TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia. <i>Breathe</i> , 2013, 9, 458-461.	0.6	0
349	Future directions for the ERS: Presidential plans. <i>European Respiratory Journal</i> , 2013, 42, 875-880.	3.1	20
350	Lessons learnt in Europe on tuberculosis surveillance, outbreaks and BCG vaccination in 2011. <i>European Respiratory Journal</i> , 2013, 41, 767-771.	3.1	5
351	A case of resistance beyond extensively drug-resistant tuberculosis in Japan. <i>European Respiratory Journal</i> , 2013, 42, 872-873.	3.1	2
352	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	3.1	346
353	Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?. <i>European Respiratory Journal</i> , 2013, 42, 1449-1453.	3.1	46
354	Drug-resistant tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 266-272.	1.2	42
355	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1. <i>European Respiratory Journal</i> , 2013, 42, 288-290.	3.1	45
356	2012: The year in review. Part 1: Tuberculosis [Year in review]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 728-737.	0.6	0
357	Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 1515-1515.	0.6	4
358	High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai, India. <i>PLoS ONE</i> , 2013, 8, e78313.	1.1	22
359	TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 289-292.	0.5	8
360	Medical treatment of pulmonary tuberculosis. , 2013, , 11-19.		1

#	ARTICLE	IF	CITATIONS
361	On linezolid efficacy and tolerability. <i>European Respiratory Journal</i> , 2012, 39, 770-772.	3.1	23
362	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	3.9	430
363	Multidrug-resistant tuberculosis today. <i>Bulletin of the World Health Organization</i> , 2012, 90, 78-78.	1.5	19
364	"Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis." M. Sester, G. Sotgiu, C. Lange, C. Giehl, E. Girardi, G.B. Migliori, A. Bossink, K. Dheda, R. Diel, J. Dominguez, M. Lipman, J. Nemeth, P. Ravn, S. Winkler, E. Huitric, A. Sandgren and D. Manissero. <i>Eur Respir J</i> 2011; 37: 100-111.. <i>European Respiratory Journal</i> , 2012, 39, 793-793.	3.1	2
365	TB and MDR-TB: what is new in 2012?. <i>Breathe</i> , 2012, 9, 100-111.	0.6	2
366	Unmasking tuberculosis in the era of antiretroviral treatment. <i>European Respiratory Journal</i> , 2012, 39, 1064-1075.	3.1	12
367	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1â€“. <i>European Respiratory Journal</i> , 2012, 40, 497-500.	3.1	20
368	Early tuberculosis treatment monitoring by Xpert ^Â MTB/RIF: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 39, 1269-1271.	3.1	61
369	Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe: Table 1. <i>European Respiratory Journal</i> , 2012, 40, 806-808.	3.1	24
370	Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. <i>European Respiratory Journal</i> , 2012, 40, 1081-1090.	3.1	99
371	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. <i>European Respiratory Journal</i> , 2012, 40, 500-503.	3.1	9
372	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 39, 1263-1266.	3.1	10
373	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. <i>Clinical Infectious Diseases</i> , 2012, 54, 1379-1380.	2.9	67
374	Risk factors associated with pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 233-240.	1.2	60
375	Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. <i>European Respiratory Journal</i> , 2012, 39, 1290-1291.	3.1	22
376	Declaration on palliative care for MDR/XDR-TB [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1418-1419.	0.6	2
377	The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. <i>Lancet, The</i> , 2012, 379, 773-775.	6.3	88
378	Scaling up interventions to achieve global tuberculosis control: progress and new developments. <i>Lancet, The</i> , 2012, 379, 1902-1913.	6.3	300

#	ARTICLE	IF	CITATIONS
379	Sanatoria for drug-resistant tuberculosis: an outdated response – Authors' reply. <i>Lancet</i> , The, 2012, 379, 2148-2149.	6.3	2
380	Multidrug-resistant tuberculosis in children can be treated. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 425-426.	4.6	2
381	Treatment of tuberculosis: have we turned the corner?. <i>Lancet</i> , The, 2012, 380, 955-957.	6.3	19
382	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. <i>European Respiratory Journal</i> , 2012, 39, 619-625.	3.1	74
383	European Union Standards for Tuberculosis Care. <i>European Respiratory Journal</i> , 2012, 39, 807-819.	3.1	188
384	GenoType MTBDR <i>sl</i> performance on clinical samples with diverse genetic background. <i>European Respiratory Journal</i> , 2012, 40, 690-698.	3.1	37
385	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. <i>Journal of Infectious Diseases</i> , 2012, 205, S147-S158.	1.9	154
386	Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. <i>European Respiratory Journal</i> , 2012, 40, 814-822.	3.1	58
387	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2012, 40, 1430-1442.	3.1	346
388	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. <i>European Respiratory Journal</i> , 2012, 40, 133-142.	3.1	42
389	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1109-1115.	2.0	11
390	Drug-Resistant Tuberculosis – Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. <i>Journal of Infectious Diseases</i> , 2012, 205, S228-S240.	1.9	140
391	Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. <i>PLoS ONE</i> , 2012, 7, e40781.	1.1	80
392	The WHO strategy for TB control and elimination. , 2012, , 242-253.		0
393	Interferon- γ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 88-99.	3.1	490
394	Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2010. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 180-185.	2.5	14
395	Treatment of drug-resistant tuberculosis – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 660-661.	4.6	0
396	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. <i>European Respiratory Journal</i> , 2011, 38, 516-528.	3.1	718

#	ARTICLE	IF	CITATIONS
397	Xpert MTB/RIF test for tuberculosis. <i>Lancet, The</i> , 2011, 378, 481-482.	6.3	4
398	Diagnosis of tuberculosis in patients with psoriasis: the need for a modified approach. <i>European Respiratory Journal</i> , 2011, 38, 232-233.	3.1	1
399	Management of MDR-TB household contacts: how difficult is it to climb the mountain? [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1137-1138.	0.6	1
400	Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. <i>European Respiratory Journal</i> , 2011, 37, 1269-1282.	3.1	116
401	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2011, 38, 730-733.	3.1	47
402	Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 100-111.	3.1	488
403	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. <i>European Respiratory Journal</i> , 2011, 37, 1283-1285.	3.1	14
404	Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). <i>European Respiratory Journal</i> , 2011, 38, 493-495.	3.1	40
405	Preventing and managing antimicrobial resistance: imperative for chest physicians. <i>European Respiratory Journal</i> , 2011, 37, 978-981.	3.1	21
406	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. <i>European Respiratory Journal</i> , 2011, 38, 1221-1223.	3.1	52
407	Interferon- γ release assays for diagnosis of active pleural tuberculosis: a developing world perspective. <i>European Respiratory Journal</i> , 2011, 38, 747-748.	3.1	5
408	ERJ peer reviewers: does this pillar of the Journal's quality need help?. <i>European Respiratory Journal</i> , 2011, 38, 251-252.	3.1	8
409	Tuberculosis: an ancient and evergreen disease. <i>European Respiratory Review</i> , 2011, 20, 69-70.	3.0	2
410	Tuberculosis and HIV co-infection: do we have a surveillance system in Europe?: Table 1â€“. <i>European Respiratory Journal</i> , 2011, 38, 1258-1260.	3.1	10
411	Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. <i>European Respiratory Journal</i> , 2011, 37, 950-959.	3.1	53
412	Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. <i>European Respiratory Journal</i> , 2011, 38, 222-224.	3.1	25
413	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. <i>PLoS ONE</i> , 2011, 6, e28066.	1.1	71
414	Research Priorities for HIV/M. tuberculosis Co-Infection. <i>The Open Infectious Diseases Journal</i> , 2011, 5, 14-20.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	1.2	18
416	Challenges and perspectives for improved management of HIV/Myco ba cterium tuberculosis co-infection. <i>European Respiratory Journal</i> , 2010, 36, 1242-1247.	3.1	39
417	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 1052-1066.	1.0	62
418	Drug-resistant tuberculosis: Past, present, future. <i>Respirology</i> , 2010, 15, 413-432.	1.3	110
419	The European Respiratory Journal targets tuberculosis. <i>European Respiratory Journal</i> , 2010, 36, 714-715.	3.1	5
420	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. <i>European Respiratory Journal</i> , 2010, 36, 208-211.	3.1	22
421	Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. <i>Thorax</i> , 2010, 65, 842-842.	2.7	1
422	From the authors:. <i>European Respiratory Journal</i> , 2010, 35, 938-940.	3.1	4
423	Tuberculosis contact investigation in low prevalence countries: a European consensus. <i>European Respiratory Journal</i> , 2010, 36, 925-949.	3.1	234
424	Extensively drug-resistant tuberculosis: back to the future. <i>European Respiratory Journal</i> , 2010, 36, 475-477.	3.1	39
425	Finding the way through the respiratory symptoms jungle: PAL can help: Respiratory Infections Assembly contribution to the celebration of 20 years of the ERS. <i>European Respiratory Journal</i> , 2010, 36, 979-982.	3.1	10
426	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 289-290.	2.5	2
427	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	3.1	444
428	TB or not TB: update from the ERS Respiratory Infection Assembly 10. <i>European Respiratory Journal</i> , 2010, 36, 665-670.	3.1	5
429	Tuberculosis on the move. <i>Lancet, The</i> , 2010, 375, 2127-2129.	6.3	30
430	XDR tuberculosis in South Africa: old questions, new answers. <i>Lancet, The</i> , 2010, 375, 1760-1761.	6.3	8
431	Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 621-629.	4.6	479
432	Tuberculosis in Europe: a problem of drug resistance or much more?. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 189-200.	1.0	19

#	ARTICLE	IF	CITATIONS
433	What About Existing Databases?. Deutsches Ärzteblatt International, 2010, 107, 435-6; author reply 436.	0.6	0
434	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 387-393.	3.1	170
435	Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Review of Respiratory Medicine, 2009, 3, 245-254.	1.0	8
436	Searching for the Tuberculosis "Needle in the Haystack". American Journal of Respiratory and Critical Care Medicine, 2009, 180, 916-917.	2.5	5
437	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 666-673.	2.5	125
438	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	1.3	10
439	Reversing the tuberculosis upwards trend: a success story in Romania. European Respiratory Journal, 2009, 33, 168-170.	3.1	13
440	Interferon- γ release assays for the diagnosis of active tuberculosis: sensible or silly?. European Respiratory Journal, 2009, 33, 1250-1253.	3.1	66
441	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. European Respiratory Journal, 2009, 33, 956-973.	3.1	487
442	Steps forward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assembly. European Respiratory Journal, 2009, 33, 1448-1453.	3.1	2
443	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	3.1	30
444	Consensus Not Yet Reached on Key Drugs for Extensively Drug-Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	2.9	6
445	Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Archivum Immunologiae Et Therapiae Experimentalis, 2009, 57, 425-433.	1.0	16
446	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infectious Diseases, 2009, 9, 142.	1.3	21
447	Defining priorities: swine-origin H1N1 and the MDR-TB epidemic. Lancet, The, 2009, 373, 2108.	6.3	10
448	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. Clinics in Chest Medicine, 2009, 30, 637-665.	0.8	64
449	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	3.1	163
450	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	3.1	131

#	ARTICLE	IF	CITATIONS
451	DOTS implementation in a post-war, United Nations-administered territory: Lessons from Kosovo. <i>Respiratory Medicine</i> , 2008, 102, 121-127.	1.3	5
452	Genotype MTBDR plus : a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 393-394.	1.8	73
453	Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey. <i>European Respiratory Journal</i> , 2008, 32, 1023-1030.	3.1	51
454	Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. <i>European Respiratory Journal</i> , 2008, 32, 1616-1624.	3.1	28
455	High incidence of sputum smear negative tuberculosis during HAART in Burkina Faso. <i>European Respiratory Journal</i> , 2008, 32, 1668-1669.	3.1	4
456	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. <i>Clinical Infectious Diseases</i> , 2008, 46, 958-959.	2.9	35
457	Update on clinical research of tuberculosis: a report from the European Respiratory Society. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 707-711.	1.0	0
458	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	3.1	67
459	Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1000-1001.	2.5	16
460	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. <i>Emerging Infectious Diseases</i> , 2008, 14, 1700-1706.	2.0	113
461	Tuberculosis, one disease, many faces. <i>Monaldi Archives for Chest Disease</i> , 2008, 69, 2-4.	0.3	7
462	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 169-172.	0.7	56
463	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. <i>PLoS ONE</i> , 2008, 3, e3417.	1.1	88
464	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	3.1	179
465	Ripped from the headlines: how can we harness communications to control TB?. <i>European Respiratory Journal</i> , 2007, 30, 194-198.	3.1	7
466	Changes in sputum composition during 15min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2007, 101, 1543-1548.	1.3	18
467	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	2.0	101
468	125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. <i>European Respiratory Journal</i> , 2007, 29, 423-427.	3.1	166

#	ARTICLE	IF	CITATIONS
469	Extensively Drug-resistant Tuberculosis, Italy and Germany. <i>Emerging Infectious Diseases</i> , 2007, 13, 780-782.	2.0	96
470	Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. <i>Respiratory Medicine</i> , 2006, 100, 1566-1572.	1.3	42
471	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in <i>Mycobacterium tuberculosis</i> Clinical Strains Isolated in Italy. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2485-2491.	1.8	98
472	Improving the TB case management: the International Standards for Tuberculosis care. <i>European Respiratory Journal</i> , 2006, 28, 687-690.	3.1	44
473	Incidence of Venous Thromboembolism in Tuberculosis Patients. <i>Respiration</i> , 2006, 73, 396-396.	1.2	42
474	Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. <i>European Respiratory Journal</i> , 2006, 28, 31-34.	3.1	107
475	Tuberculosis care and control. <i>Bulletin of the World Health Organization</i> , 2006, 84, 428-428.	1.5	4
476	FREQUENCY OF VENOUS THROMBOEMBOLISM AMONG PATIENTS WITH TUBERCULOSIS DURING SHORT-COURSE CHEMOTHERAPY. <i>Chest</i> , 2005, 128, 404S.	0.4	0
477	Comparison of Tuberculin Skin test and Quantiferon immunological assay for latent Tuberculosis infection. <i>Monaldi Archives for Chest Disease</i> , 2005, 63, 158-62.	0.3	4
478	Evaluation of a New Line Probe Assay for Rapid Identification of <i>gyrA</i> Mutations in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2928-2933.	1.4	49
479	<i>Mycobacterium tuberculosis</i> Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	2.0	7
480	European framework to decrease the burden of TB/HIV. <i>European Respiratory Journal</i> , 2004, 24, 493-501.	3.1	21
481	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. <i>European Respiratory Journal</i> , 2003, 21, 129-134.	3.1	12
482	European framework for tuberculosis control and elimination in countries with a low incidence. <i>European Respiratory Journal</i> , 2002, 19, 765-775.	3.1	268
483	Microbiological confirmation of tuberculosis cases at diagnosis and at the end of treatment in Italy. <i>European Journal of Epidemiology</i> , 2000, 16, 719-724.	2.5	3
484	Induced Sputum Cellularity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1172-1174.	2.5	199
485	Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2537.	3.8	417
486	Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture- versus the smear-based methods. <i>European Respiratory Journal</i> , 1999, 13, 900.	3.1	7

#	ARTICLE	IF	CITATIONS
487	Tuberculosis management in Europe Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.. European Respiratory Journal, 1999, 14, 978.	3.1	87
488	Tuberculosis management in Europe Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.. European Respiratory Journal, 1999, 14, 978-992.	3.1	67
489	Bronchoalveolar lavage causes decrease in PaO ₂ , increase in (A- \dot{V}) gradient value and bronchoconstriction in asthmatics. Respiratory Medicine, 1998, 92, 191-197.	1.3	16
490	Cost-Effectiveness Analysis of Invasive and Noninvasive Tests in High Risk Patients Treated With Amiodarone After Acute Myocardial Infarction. Journal of the American College of Cardiology, 1998, 31, 1481-1489.	1.2	9
491	Conditioned inhibition of antibody response and CD4 positive cells. Physiology and Behavior, 1998, 64, 395-398.	1.0	7
492	Comparison of Two Methods of Processing Induced Sputum: Selected versus Entire Sputum. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 665-668.	2.5	57
493	Standardized tuberculosis treatment outcome monitoring in Europe. European Respiratory Journal, 1998, 12, 505-510.	3.1	131
494	Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. European Respiratory Journal, 1997, 10, 2853-2860.	3.1	129
495	Induced sputum to assess airway inflammation: a study of reproducibility. Clinical and Experimental Allergy, 1997, 27, 1138-1144.	1.4	93
496	Surveillance of tuberculosis in Europe. European Respiratory Journal, 1996, 9, 1097-1104.	3.1	111
497	Economic analysis of two structured treatment and teaching programs on asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 313-319.	2.7	46
498	Validation of the surveillance system for new cases of tuberculosis in a province of Northern Italy. European Respiratory Journal, 1995, 8, 1252-1258.	3.1	21
499	Determinants of Stunting and Recovery from Stunting in Northwest Uganda. International Journal of Epidemiology, 1994, 23, 782-786.	0.9	43
500	On q_4 -sets of type $(0, q_4, q_2)$ in projective planes of order $q \equiv 0 \pmod{4}$. Discrete Mathematics, 1994, 129, 149-158.	0.4	3
501	Tuberculosis control in Europe and international migration. European Respiratory Journal, 1994, 7, 1545-1553.	3.1	109
502	Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. Tubercle and Lung Disease, 1993, 74, 215.	2.1	2
503	Anthropometry and childhood mortality in northwest and southwest Uganda.. American Journal of Public Health, 1993, 83, 1616-1618.	1.5	31
504	Tuberculosis and HIV infection association in a rural district of northern Uganda: epidemiological and clinical considerations. Tubercle and Lung Disease, 1992, 73, 285-290.	2.1	17

#	ARTICLE	IF	CITATIONS
505	Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. <i>Tubercle and Lung Disease</i> , 1992, 73, 145-149.	2.1	37
506	New and repurposed drugs. , 0, , 179-204.		4
507	Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20210384.	0.4	17